Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,728.40
(
0.03%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
105.55
(
1.07%
)
Bitcoin
71,100.72
(
1.72%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 116360

Wednesday, 04/20/2011 7:09:47 PM

Wednesday, April 20, 2011 7:09:47 PM

Post# of 257262
In other GILD news, an all-oral phase-2 trial testing GS5885 + GS9451+ GS9190 + ribavirin is planned to begin as soon as the FDA clears the protocol.

GS5885 is an NS5A inhibitor, GS9190 is a non-nuke, and GS9451 is a PI that’s the successor to GS9256 (which is evidently defunct).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Unleash the power of Level 2

Spot liquidity moves with access to US order books.

Sign Up